Josef Goldufsky
Senior Scientist II Invenra Inc.
Seminars
Wednesday 24th June 2026
T-Body™ Trispecific TAA/CD3/CD28 Co-Stimulatory Antibody Optimization Drives Superior Tumor-Directed T-Cell Engagement
10:00 am
- Optimization of TAA/CD3/CD28 affinity and trispecific antibody format drives on-target potency and minimizes off-tumor toxicity
- TAA/CD3/CD28 targeted T-Body™ trispecific antibodies preserve T-cell polyfunctionality, maintaining robust cytokine secretion and cytolytic capacity
- CD28 co-stimulation within the T-Body™ trispecific antibody format rescues T-cells from exhaustion allowing for durable antitumor responses
